Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma

European Journal of Haematology

Volumn 64, Issue 2, 2000, Pages 121-129

  Abildgaard, N ^a   Glerup, H ^a   Rungby, J ^a   Bendix Hansen, K ^a   Kassem, M ^a   Brixen, K ^a   Heickendorff, L ^a   Nielsen, J L ^a   Eriksen, E F ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Bone specific alkaline phosphatase; Collagen derived peptides; Cytokines; Histomorphometry; Myeloma bone disease; Osteocalcin

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN TYPE 1; CYTOKINE; DEOXYPYRIDINOLINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; LYMPHOTOXIN; OSTEOCALCIN; PAMIDRONIC ACID; PYRIDINOLINE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BONE DISEASE; BONE METABOLISM; CELL DIFFERENTIATION; CLINICAL ARTICLE; COLLAGEN DEGRADATION; CONTROLLED STUDY; DOSE CALCULATION; FEMALE; HUMAN; HUMAN TISSUE; MALE; MORPHOMETRICS; MULTIPLE MYELOMA; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BIOPSY; BONE AND BONES; BONE MARROW; BONE RESORPTION; COLLAGEN; COLLAGEN TYPE I; FEMALE; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; ISOENZYMES; LYMPHOTOXIN-ALPHA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OSTEOBLASTS; OSTEOCLASTS; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN; RECEPTORS, INTERLEUKIN-6; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034021345     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2000.90074.x     Document Type: Article

References (43)

1. 1. Klein B, Bataille R. Cytokine network in human multiple myeloma. Hematol/Oncol Clin N Am 1992;6:273-284.
2. 2. Bataille R, Chappard D, Marcelli C, et al. Osteoblasl stimulation in multiple myeloma lacking lytic lesions. Br J Haematol 1990;76:484-487.
3. 3. Bataille R, Chappard D, Marcelli C, et al. Mechanisms of bone destruction in multiple myeloma: The importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol 1989;7:1909-1914.
4. 4. Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF/IL-6 for human multiple myeloma. Nature 1988;332:83-85.
5. 5. Klein B, Zhang XG, Jourdan M, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989;73:517-526.
6. 6. Roodman GD. Interleukin-6: An osleotropic factor? J Bone Miner Res 1992;7:475-478.
7. 7. Pulkki K, Pelliniemi TT, Rajamäki A, Tienhaara A, Laakso M, Lahtinen R. Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Br J Haematol 1996;92:370-374.
8. 8. Kawano M, Yamamoto I, Iwato K, et al. Interleukin-1 beta rather than lymphotoxin as the major bone resorbing activator in human multiple myeloma. Blood 1989;73: 1646-1649.
9. 9. Carter A, Merchov S, Silivan-Draxler I, Tatarsky I. The role of interleukin-1 and tumour necrosis factor-alfa in human multiple myeloma. Br J Haematol 1990;74:424-431.
10. 10. Garrett IR, Durie BGM, Nedwin GE, et al. Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. N Engl J Med 1987;317:526-532.
11. 11. Lichtenstein A, Berenson J, Norman D, Chang MP, Carlile, A. Production of cytokines by marrow cells obtained from patients with multiple myeloma. Blood 1989;74:1266-1273.
12. 12. Mundy GR, Boyce B, Hughes D, et al. The effects of cytokines and growth factors on osteoblastic cells. Bone 1995;17 (suppl 2):71S-75S.
13. 13. Abildgaard N, Bendix-Hansen K, Kristensen JE, et al. Bone marrow fibrosis and disease activity in multiple myeloma monitored by the aminoterminal propeptide of procollagen III in serum. Br J Haematol 1997;99: 641-648.
14. 14. Taube T, Beneton MNC, McCloskey EV, Rogers S, Greaves M, Kanis JA. Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol 1992;49:192-198.
15. 15. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996;334: 488-493.
16. 16. Eriksen EF. Normal and pathological remodelling of human trabecular bone: Three-dimensional reconstruction of the remodelling cycle in normals and in metabolic bone disease. Endocrine Rev 1986;7:379-408.
17. 17. Eriksen EF, Brixen K, Charles P. New markers of bone metabolism: clinical use in metabolic bone disease. Eur J Endocrinol 1995;132:251-263.
18. 18. Elomaa I, Virkkunen P, Risteli L, Risteli J. Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. Br J Cancer 1992;66: 337-341.
19. 19. Elomaa I, Risteli L, Laakso M, lahtinen R, Virkkunen P, Risteli J. Monitoring the action of clodronate with type I collagen metabolites in multiple myeloma. Eur J Cancer 1996;32:1166-1170.
20. 20. Abildgaard N, Nielsen JL, Heickendorff L. Connective tissue components in serum in multiple myeloma: Analyses of propeptides of type I and type III procollagens, type I collagen telopeptide, and hyaluronan. Am J Hematol 1994; 46:173-178.
21. 21. Abildgaard N, Bentzen SM, Nielsen JL, Heickendorff L. Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP). Br J Haematol 1997;96:103-110.
22. 22. Peest D, Deicher W, Harms P, et al. Pyridinium cross-links in multiple myeloma: correlation with clinical parameters and use for monitoring of intravenous clodronale therapy -a pilot study of the German Myeloma Treatment Group (GMTG). Eur J Cancer 1996;32A:2053-2057.
23. 23. Pecherstorfer M, Seibel MJ, Woitge HW, et al. Bone resorption in multiple myeloma and monoclonal gammopathy of undetermined significance: quantification by urinary pyridinium cross-links of collagen. Blood 1997;90:3743 3750.
24. 24. Carlson K, Larsson A, Simonsson, B, Turesson I, Westin J, Ljunghall S. Evaluation of bone disease in multiple myeloma: a comparison between the resorption markers urinary deoxypyridinoline/creatinine (DPD) and senim ICTP, and an evaluation of the DPD/osteocalcin and ICTP/osteocalcin ratios. Eur J Haematol 1999;62:300-306.
25. 25. Bataille R, Delmas PD, Chappard D, Sany J. Abnormal serum bone gla protein levels in multiple myeloma. Crucial role of bone formation and prognostic implications. Cancer 1990;66:167-172.
26. 26. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: A new serum marker of bone collagen degradation. Clin Chem 1993; 39:635-640.
27. 27. Hanson DA, Weis MAE, Bollen A, Maslan SL, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked W-telopeptides in urine. J Bone Miner Res 1992;7:1251-1258.
28. 28. Eyre DR, Koob TJ, van Ness KP. Quantitation of hydroxy-pyridinium crosslinks in collagen by high-performance liquid chromatography. Ann Biochem 1984;137:380-388.
29. 29. Melkko J, Niemi J, Risteli L, Risteli J. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 1990;36:1328-1332.
30. 30. Brixen K, Nielsen HK, Eriksen EF, Charles P, Mosekilde L. Efficacy of wheat germ lectin-precipitated alkaline phosphatase in serum as an estimator of bone mineralisation rate: comparison to serum total alkaline phosphatase and serum bone gla protein. Cal Tissue Int 1989;44:93-98.
31. 31. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36:842-854.
32. 32. Brincker H, Westin J, Abildgaard N, et al. Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Br J Haematol 1998;101:280-286.
33. 33. Abildgaard N, Rungby J, Glerup H, et al. Long-term oral pamidronale treatment inhibits osteoclastic bone resorption and bone turnover in multiple myeloma without affecting osteoblastic function. Eur J Haematol 1998;61:128-134.
34. 34. Parfitt AM, Drezner MK, Glorieoex FH, et al. Bone histomorphometry: Standardization of nomenclature, symbols and units. J Bone Miner Res 1987;2:595-610.
35. 35. Price PA, Nishimoto SK. Radioimmunoassay for the vitamin K-dependent protein of bone and its discovery in plasma. Proc Natl Acad Sci USA 1980;77:2234-2238.
36. 36. Behr W, Barnert J. Quantitation of bone alkaline phosphatase in serum by precipitation with wheat-germ lectin: a simplified method and its clinical plausibility. Clin Chem 1986;32:1960-1966.
37. 37. Evans CE, Allen J, Parker J. Adhesion of human osteoblast-like cells in culture is impaired by exposure to factors secreted by multiple myeloma cells. Eur J Musculoskel Res 1994;3: 137-144.
38. 38. Heldin CH, Miyazono K, Ten Duke P. TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature 1997;390:465-471.
39. 39. Kretzmar M, Doody J, Massague J. Opposing BMP and EGF signalling pathways converge on the TGF-β family mediator Smadl. Nature 1997;389:618-622.
40. 40. Børset M, Lien E, Espevik T, Helseth E, Waage A. Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-Met in human myeloma cell lines. J Biol Chem 1996;271:24,655-24,661.
41. 41. Seidel C, Børset M, Turesson I, Abildgaard N, Sundan A, Waage A. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. Blood 1998;91:806-812.
42. 42. Valentin-Opran A, Charhon SA, Meunier PJ, Edouard CM, Arlot ME. Quantitative histology of myeloma-induced bone changes. Br J Haematol 1982;52:601-610.
43. 43. Bataille R, Chappard D, Basle M. Excessive bone resorption in human plasmacytomas: direct induction by tumour cells in vivo. Br J Haematol 1995;90:721-724.